BACKGROUND:Microvascular coronary dysfunction (MCD) is associated with symptoms and signs of ischemia, and also adverse outcomes in women without macrovascular obstructive coronary artery disease (M-CAD). Although MCD can be quantified using coronary flow reserve (CFR), treatment is poorly defined. HYPOTHESIS: Phosphodiesterase type 5 (PDE-5) inhibition acutely improves MCD in these women. METHODS: The subjects were 23 symptomatic women (age 54 ± 11 y) participating in an ancillary study of the Women's Ischemia Syndrome Evaluation with baseline CFR ≤3.0 (Doppler flow wire and intracoronary adenosine) and without M-CAD. Coronary flow reserve was remeasured 45 minutes after PDE-5 inhibition (100 mg oral sildenafil). The primary measure of interest was change in CFR adjusted for baseline variables. RESULTS: The relationship between log(2)-transformed CFR post-PDE-5 inhibition (adjusted) and baseline was different from the line of identity (slope: 0.55 vs 1.0, P = 0.008; intercept: 0.73 vs 0.0, P = 0.01), indicating that PDE-5 inhibition improves CFR and the lower the baseline CFR, the greater the response. Among women with baseline CFR ≤2.5 (n = 11), CFR increased from 2.1 ± 0.2 to 2.7 ± 0.6 (P = 0.006). For women with baseline CFR >2.5 (n = 12), CFR did not change (3.1 ± 0.3 to 3.0 ± 0.6; P = 0.70). CONCLUSIONS:For women with symptoms and signs of ischemia and no M-CAD, PDE-5 inhibition is associated with acute improvement in CFR, and the effect concentrates among those with CFR ≤2.5. If these acute effects are sustained, then PDE-5 inhibition would provide a rational strategy for management of MCD in symptomatic women without M-CAD. The longer-term effects warrant study in a randomized trial using a sustained-acting PDE-5 inhibitor.
RCT Entities:
BACKGROUND:Microvascular coronary dysfunction (MCD) is associated with symptoms and signs of ischemia, and also adverse outcomes in women without macrovascular obstructive coronary artery disease (M-CAD). Although MCD can be quantified using coronary flow reserve (CFR), treatment is poorly defined. HYPOTHESIS: Phosphodiesterase type 5 (PDE-5) inhibition acutely improves MCD in these women. METHODS: The subjects were 23 symptomatic women (age 54 ± 11 y) participating in an ancillary study of the Women's Ischemia Syndrome Evaluation with baseline CFR ≤3.0 (Doppler flow wire and intracoronary adenosine) and without M-CAD. Coronary flow reserve was remeasured 45 minutes after PDE-5 inhibition (100 mg oral sildenafil). The primary measure of interest was change in CFR adjusted for baseline variables. RESULTS: The relationship between log(2)-transformed CFR post-PDE-5 inhibition (adjusted) and baseline was different from the line of identity (slope: 0.55 vs 1.0, P = 0.008; intercept: 0.73 vs 0.0, P = 0.01), indicating that PDE-5 inhibition improves CFR and the lower the baseline CFR, the greater the response. Among women with baseline CFR ≤2.5 (n = 11), CFR increased from 2.1 ± 0.2 to 2.7 ± 0.6 (P = 0.006). For women with baseline CFR >2.5 (n = 12), CFR did not change (3.1 ± 0.3 to 3.0 ± 0.6; P = 0.70). CONCLUSIONS: For women with symptoms and signs of ischemia and no M-CAD, PDE-5 inhibition is associated with acute improvement in CFR, and the effect concentrates among those with CFR ≤2.5. If these acute effects are sustained, then PDE-5 inhibition would provide a rational strategy for management of MCD in symptomatic women without M-CAD. The longer-term effects warrant study in a randomized trial using a sustained-acting PDE-5 inhibitor.
Authors: Isabelle Schmid; Dominique Didier; Thomas Pfammatter; Ali Garachemani; Martin Fleisch; Miles A Kirchin; Bernhard Meier Journal: Int J Cardiol Date: 2007-03-21 Impact factor: 4.164
Authors: Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Kevin E Kip; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Gerald M Pohost; George Sopko Journal: Circulation Date: 2006-08-21 Impact factor: 29.690
Authors: C Noel Bairey Merz; Leslee J Shaw; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Carl J Pepine; Sunil Mankad; Barry L Sharaf; William J Rogers; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko Journal: J Am Coll Cardiol Date: 2006-02-07 Impact factor: 24.094
Authors: Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Timothy R Wessel; Christopher B Arant; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko Journal: J Am Coll Cardiol Date: 2006-02-07 Impact factor: 24.094
Authors: B Delia Johnson; Leslee J Shaw; Steven D Buchthal; C Noel Bairey Merz; Hee-Won Kim; Katherine N Scott; Mark Doyle; Marian B Olson; Carl J Pepine; Jan den Hollander; Barry Sharaf; William J Rogers; Sunil Mankad; John R Forder; Sheryl F Kelsey; Gerald M Pohost Journal: Circulation Date: 2004-06-14 Impact factor: 29.690
Authors: Mark A Marinescu; Adrián I Löffler; Michelle Ouellette; Lavone Smith; Christopher M Kramer; Jamieson M Bourque Journal: JACC Cardiovasc Imaging Date: 2015-02
Authors: Athanasios Charalampopoulos; Luke S Howard; Ioanna Tzoulaki; Wendy Gin-Sing; Julia Grapsa; Martin R Wilkins; Rachel J Davies; Petros Nihoyannopoulos; Susan B Connolly; J Simon R Gibbs Journal: Pulm Circ Date: 2014-12 Impact factor: 3.017
Authors: Wilmer W Nichols; Scott J Denardo; Jonathan B Davidson; Tianyao Huo; C Noel Bairey Merz; Carl J Pepine Journal: Am Heart J Date: 2015-08-28 Impact factor: 4.749